AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3484828 — intervention group
Group type: COMPARATOR
Intervention: Higher amplitude stimulation
Number of subjects: 192
Study 31564046 — intervention group
Group type: EXPERIMENTAL
Intervention: Short telomeres (200 base pairs shorter)
Number of subjects: 66567
Study 31564046 — intervention group
Group type: EXPERIMENTAL
Intervention: Short telomeres (6 alleles)
Number of subjects: 66567
Study 29653820 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/d)
Number of subjects: 134
Study 29653820 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/pemetrexed (LL3)
Number of subjects: 134
Study 29653820 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/gemcitabine (LL6)
Number of subjects: 134
Study 29653820 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (250 mg/d; LL7)
Number of subjects: 134
Study 28760215 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail-outs sent on behalf of cardiologist at 4, 8, 20, 32, and 44 weeks post-MI
Number of subjects: 2742
Study 28760215 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail-outs plus automated interactive voice response system telephone calls and trained lay health workers' calls
Number of subjects: 2742
Study 28760215 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2742
Study 28760215 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 2742
Study 25626910 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy and 360° endolaser therapy
Number of subjects: 60
Study 25626910 — intervention group
Group type: COMPARATOR
Intervention: Pars plana vitrectomy and an encircling scleral buckle
Number of subjects: 60
Study 22964869 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic peer support intervention for 6 weeks after surgery
Number of subjects: 129
Study 22964869 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 129
Study 21906709 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 3602
Study 21906709 — intervention group
Group type: COMPARATOR
Intervention: Conventional stenting (after predilatation)
Number of subjects: 3602
Study 18412565 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% Aluminium Chlorohydrate (ACH) aqueous solution
Number of subjects: 4
Study 18412565 — intervention group
Group type: EXPERIMENTAL
Intervention: 4%, 8%, or 12% Aluminium Chlorohydrate (ACH) aqueous solution
Number of subjects: 4
Study 18412565 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated summer conditions with thermal stimulation during application phase
Number of subjects: 4
Study 16331608 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCD algorithm
Number of subjects: 255
Study 16331608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive education with photographs (Cog)
Number of subjects: 255
Study 16331608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive education with photographs + explanations (Cog-Ex)
Number of subjects: 255
Study 16331608 — intervention group
Group type: COMPARATOR
Intervention: No intervention (NI)
Number of subjects: 255
Study 16331608 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCD algorithm under stress (T2)
Number of subjects: 255
Study 16331608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive education with photographs (Cog) under stress (T2)
Number of subjects: 255
Study 12494207 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40‐80 mg/day) for 24 weeks
Number of subjects: 24
Study 9862555 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (0, 125, and 375 microg/kg)
Number of subjects: 48
Study 9862555 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (125 microg/kg)
Number of subjects: 48
Study 9862555 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (375 microg/kg)
Number of subjects: 48
Study 7877305 — intervention group
Group type: EXPERIMENTAL
Intervention: Acadesine (low-dose and high-dose)
Number of subjects: 34
Study 7877305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 7877305 — intervention group
Group type: EXPERIMENTAL
Intervention: Acadesine (in vitro)
Number of subjects: 34
Study 7877305 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (in vitro)
Number of subjects: 34
Study 7877305 — intervention group
Group type: EXPERIMENTAL
Intervention: Acadesine
Number of subjects: 34
Study 2212216 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (250 mg, three times a day for one week) with scaling and root planing
Number of subjects: 0
Study 2212216 — intervention group
Group type: COMPARATOR
Intervention: Placebo with scaling and root planing
Number of subjects: 0
Study 355807 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual milk therapy
Number of subjects: 1
Study 355807 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind challenges
Number of subjects: 1
Study 30656824 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic nadroparin (LMWH)
Number of subjects: 252
Study 30656824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 30359166 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive ondansetron (8 mg/daily)
Number of subjects: 85
Study 30359166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 27288217 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP5‐HB‐IPV‐Hib Group
Number of subjects: 1315
Study 27288217 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 1315
Study 25052733 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Reduction and Internal Fixation (ORIF)
Number of subjects: 56
Study 25052733 — intervention group
Group type: COMPARATOR
Intervention: Closed Reduction and Maxillomandibular Fixation (MMF)
Number of subjects: 56
Study 22752865 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin 200 mg twice daily for 10 days
Number of subjects: 1164
Study 22752865 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 125 mg 4 times daily for 10 days
Number of subjects: 1164
Study 21071074 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone short message service (SMS) intervention
Number of subjects: 538
Study 21071074 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 538
Study 17579629 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus etoposide (CE); carboplatin AUC 5 IV on day 1 and etoposide 80 mg/m² IV on days 1-3, with G-CSF support for 4 courses.
Number of subjects: 220
Study 17579629 — intervention group
Group type: COMPARATOR
Intervention: Split doses of cisplatin plus etoposide (SPE); cisplatin 25 mg/m² IV on days 1-3 and etoposide 80 mg/m² IV on days 1-3, with G-CSF support for 4 courses.
Number of subjects: 220
Study 17579629 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus etoposide (CE)
Number of subjects: 220
Study 17579629 — intervention group
Group type: COMPARATOR
Intervention: Split doses of cisplatin plus etoposide (SPE)
Number of subjects: 220
Study 16100444 — intervention group
Group type: COMPARATOR
Intervention: FPG <5.0 mM/L (Group 1)
Number of subjects: 2964
Study 16100444 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.6< or =FPG <6.1 mM/L (Group 3)
Number of subjects: 2964
Study 16100444 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.1< or =FPG <7.0 mM/L (Group 4)
Number of subjects: 2964
Study 12085177 — intervention group
Group type: EXPERIMENTAL
Intervention: Marimastat (10 mg b.d.)
Number of subjects: 369
Study 12085177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study 9449906 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream
Number of subjects: 311
Study 9449906 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% imiquimod cream
Number of subjects: 311
Study 9449906 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 311
Study 9449906 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 311
Study 8903664 — intervention group
Group type: COMPARATOR
Intervention: Mibefradil 150 mg (acute study)
Number of subjects: 18
Study 8903664 — intervention group
Group type: COMPARATOR
Intervention: Verapamil SR 240 mg (acute study)
Number of subjects: 18
Study 8903664 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem 240 mg (acute study)
Number of subjects: 18
Study 8903664 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg daily (chronic study)
Number of subjects: 18
Study 8903664 — intervention group
Group type: COMPARATOR
Intervention: Verapamil SR 240 mg daily (chronic study)
Number of subjects: 18
Study 2295997 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fluoride mouthrinsing and fluoride tablets
Number of subjects: 1640
Study 2295997 — intervention group
Group type: COMPARATOR
Intervention: Fluoride tablets (2.2 mg NaF daily)
Number of subjects: 1640
Study 2295997 — intervention group
Group type: COMPARATOR
Intervention: Fluoride mouthrinsing (0.2% NaF solution weekly)
Number of subjects: 1640
Study 271588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride jelly (single application)
Number of subjects: 0
Study 271588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride jelly (four times continuous daily application)
Number of subjects: 0
Study 271588 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminofluoride jelly (single application)
Number of subjects: 0
Study 271588 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminofluoride jelly (four times continuous daily application)
Number of subjects: 0
Study 31068298 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg/kg sufentanil combined with TAP block
Number of subjects: 60
Study 31068298 — intervention group
Group type: COMPARATOR
Intervention: 2 μg/kg sufentanil without TAP block
Number of subjects: 60
Study 28536417 — intervention group
Group type: EXPERIMENTAL
Intervention: doppel active condition (device turned on with heartbeat-like vibration)
Number of subjects: 2
Study 28536417 — intervention group
Group type: COMPARATOR
Intervention: Control group (device turned off)
Number of subjects: 2
Study 26088180 — intervention group
Group type: EXPERIMENTAL
Intervention: High target pCO2 group (aimed at pCO2 values of 55‐65 mm Hg on days 1‐3, 60‐70 mm Hg on days 4‐6, and 65‐75 mm Hg on days 7‐14)
Number of subjects: 362
Study 26088180 — intervention group
Group type: COMPARATOR
Intervention: Control group (target pCO2 40‐50 mmHg on days 1‐3, 45‐55 mm Hg on days 4‐6, and 50‐60 mm Hg on days 7‐14)
Number of subjects: 362
Study 26088180 — intervention group
Group type: EXPERIMENTAL
Intervention: High target pCO2 group
Number of subjects: 362
Study 26088180 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 362
Study 23163792 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoughts of death
Number of subjects: 0
Study 23163792 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoughts of survival
Number of subjects: 0
Study 23382279 — intervention group
Group type: EXPERIMENTAL
Intervention: Saunders traction
Number of subjects: 39
Study 23382279 — intervention group
Group type: EXPERIMENTAL
Intervention: Saunders traction + TENS
Number of subjects: 39
Study 23382279 — intervention group
Group type: COMPARATOR
Intervention: TENS only
Number of subjects: 39
Study 19707744 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (0.5 U/kg body weight)
Number of subjects: 18
Study 19707744 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin (0.5 U/kg body weight)
Number of subjects: 18
Study 19707744 — intervention group
Group type: EXPERIMENTAL
Intervention: Both insulin detemir and NPH insulin
Number of subjects: 18
Study 18158020 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg BCG
Number of subjects: 152
Study 18158020 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg BCG
Number of subjects: 152
Study 18158020 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg BCG
Number of subjects: 152
Study 15342159 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback gain (increased)
Number of subjects: 13
Study 15342159 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback rehabilitation protocol (enhanced gain)
Number of subjects: 13
Study 12357261 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator and radiofrequency ablation in addition to antiarrhythmic drugs
Number of subjects: 0
Study 12357261 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drugs
Number of subjects: 0
Study 10027342 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 20 mg with 5-HT3 antagonists
Number of subjects: 69
Study 10027342 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg with 5-HT3 antagonists
Number of subjects: 69
Study 10027342 — intervention group
Group type: COMPARATOR
Intervention: Medium-dose dexamethasone (8 mg) with 5-HT3 antagonists
Number of subjects: 69
Study 1801562 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-efficacy group
Number of subjects: 0
Study 1801562 — intervention group
Group type: EXPERIMENTAL
Intervention: Low self-efficacy group
Number of subjects: 0
Study 1801562 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 0
Study 6357659 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg taken at 1200
Number of subjects: 4
Study 6357659 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 4
Study 31905228 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhax 0.5 μg
Number of subjects: 45
Study 31905228 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhax 2.5 μg
Number of subjects: 45
Study 31905228 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhax 10 μg
Number of subjects: 45
Study 31905228 — intervention group
Group type: COMPARATOR
Intervention: Typhim Vi (25 μg)
Number of subjects: 45
Study 31905228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31805104 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric-acid dialysate with dCa1.50 (C1.5)
Number of subjects: 18
Study 31805104 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetic-acid dialysate with dCa1.25 (A1.25)
Number of subjects: 18
Study 31805104 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetic-acid dialysate with dCa1.50 (A1.5)
Number of subjects: 18
Study 28638008 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary veins isolation during CABG
Number of subjects: 117
Study 28638008 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 117
Study 27101283 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA injections at weeks 0, 16, and 32
Number of subjects: 24
Study 27101283 — intervention group
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA injections
Number of subjects: 24
Study 25002006 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 674
Study 25002006 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care and psychotherapy
Number of subjects: 674
Study 25002006 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care and education and psychotherapy
Number of subjects: 674
Study 25002006 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care and education
Number of subjects: 674
Study 22198448 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 5 or 10 mg
Number of subjects: 324
Study 22198448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study 20958294 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA injection using the PREEMPT paradigm (both fixed and follow-the-pain sites)
Number of subjects: 0
Study 20958294 — intervention group
Group type: COMPARATOR
Intervention: OnabotulinumtoxinA injection
Number of subjects: 0
Study 18482870 — intervention group
Group type: EXPERIMENTAL
Intervention: DNIC condition (ischemic arm pain)
Number of subjects: 57
Study 18482870 — intervention group
Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 57
Study 15805889 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 300
Study 15805889 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 300
Study 15805889 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (subgroup with recurrent/persistent otitis media)
Number of subjects: 300
Study 15805889 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting (subgroup with recurrent/persistent otitis media)
Number of subjects: 300
Study 15805889 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (subgroup diagnosed with otitis media at inclusion)
Number of subjects: 300
Study 15805889 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting (subgroup diagnosed with otitis media at inclusion)
Number of subjects: 300
Study 14582441 — intervention group
Group type: EXPERIMENTAL
Intervention: Structum
Number of subjects: 373
Study 14582441 — intervention group
Group type: COMPARATOR
Intervention: Control (NSAID)
Number of subjects: 373
Study 10605180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix 60 mg
Number of subjects: 20
Study 10605180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Number of subjects: 20
Study 9124627 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E treatment
Number of subjects: 2
Study 9124627 — intervention group
Group type: COMPARATOR
Intervention: Untreated (Control)
Number of subjects: 2
Study 8204918 — intervention group
Group type: COMPARATOR
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine with methylprednisolone)
Number of subjects: 65
Study 8204918 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD plus cisplatinum (ABVD-PLT)
Number of subjects: 65
Study 3541165 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 8
Study 3541165 — intervention group
Group type: COMPARATOR
Intervention: Sulindac
Number of subjects: 8
Study 30193843 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA administration (100 mg/day for 4 weeks)
Number of subjects: 10
Study 27072219 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy (ART) - 50 Gy in 25 fractions, six fractions weekly
Number of subjects: 106
Study 27072219 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiation (CRT) - 50 Gy in 25 fractions with weekly cisplatin
Number of subjects: 106
Study 25566589 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine (15 mg, 3 mL)
Number of subjects: 60
Study 25566589 — intervention group
Group type: COMPARATOR
Intervention: Isobaric bupivacaine (15 mg, 3 mL)
Number of subjects: 60
Study 22622909 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation On
Number of subjects: 34
Study 22622909 — intervention group
Group type: COMPARATOR
Intervention: Stimulation Off
Number of subjects: 34
Study 20447305 — intervention group
Group type: EXPERIMENTAL
Intervention: Agmatine sulfate 2.670 g/day for 14 days
Number of subjects: 99
Study 20447305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 18797833 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of palatal implants (SB group) within 72 hours of insertion.
Number of subjects: 16
Study 18797833 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading of palatal implants (KB group) after a 12-week healing period.
Number of subjects: 16
Study 15844302 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapericardial urokinase along with conventional treatment
Number of subjects: 94
Study 15844302 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone (including pericardiocentesis and drainage)
Number of subjects: 94
Study 12051573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (N) 1 g
Number of subjects: 32
Study 12051573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (N) 2 g
Number of subjects: 32
Study 12051573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (N) 3 g
Number of subjects: 32
Study 12051573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (N) 4 g
Number of subjects: 32
Study 12051573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12051573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (N) with food
Number of subjects: 32
Study 12051573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (N) without food
Number of subjects: 32
Study 12051573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (N)
Number of subjects: 32
Study 10082778 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium diet (4.67 g/L)
Number of subjects: 0
Study 10082778 — intervention group
Group type: COMPARATOR
Intervention: Normal calcium diet (2.0 g/L)
Number of subjects: 0
Study 10082778 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium diet (4.67 g/L) and Normal calcium diet (2.0 g/L)
Number of subjects: 0
Study 7728405 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet (E028)
Number of subjects: 24
Study 7728405 — intervention group
Group type: COMPARATOR
Intervention: Control group (23 patients)
Number of subjects: 24
Study 1932650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative blood recovery system (IBRS)
Number of subjects: 66
Study 1932650 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediastinal drainage blood recovery system (MBRS) combined with IBRS
Number of subjects: 66
Study 1932650 — intervention group
Group type: COMPARATOR
Intervention: Homologous blood (HB)
Number of subjects: 66
Study 7153190 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized contingency
Number of subjects: 0
Study 7153190 — intervention group
Group type: EXPERIMENTAL
Intervention: Group contingency based on group average
Number of subjects: 0
Study 7153190 — intervention group
Group type: EXPERIMENTAL
Intervention: Group contingency based on designated low-achieving student
Number of subjects: 0
Study 7153190 — intervention group
Group type: EXPERIMENTAL
Intervention: Group contingency based on randomly selected student
Number of subjects: 0
Study 30840961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent-full-standard-dose tamsulosin
Number of subjects: 93
Study 30840961 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tamsulosin
Number of subjects: 93
Study 30840961 — intervention group
Group type: COMPARATOR
Intervention: Full-standard-dose tamsulosin (Control)
Number of subjects: 93